Related Experiment Video
Updated: Mar 18, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
10.5K
Implementing Algorithm-Guided Warfarin Dosing in an Ethnically Diverse Patient Population Using Electronic Health
A Owusu Obeng1,2, T Kaszemacher3, N S Abul-Husn3
1The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA. aniwaa.owusu-obeng@mssm.edu.
Clinical Pharmacology and Therapeutics
|July 10, 2016
Summary
Pharmacogenetic-guided warfarin dosing is more accurate than standard dosing. A new strategy uses electronic health records and genetic testing for multiethnic populations to improve warfarin dosing accuracy.
Area of Science:
- Pharmacogenomics
- Clinical Pharmacology
- Genetics
Background:
- Pharmacogenetic-guided warfarin dosing faces challenges due to inconsistent clinical trial data.
- Existing algorithms often lack alleles common in non-white populations, limiting multiethnic application.
Purpose of the Study:
- To develop a strategy for multiethnic, algorithm-guided warfarin dosing using preemptive genetic testing.
- To address limitations of current warfarin dosing algorithms by incorporating race complexity and leveraging electronic health records.
Main Methods:
- Developed a novel strategy for warfarin dosing.
- Integrated electronic health records for algorithm variables.
- Utilized preemptive genetic testing and accounted for racial complexities.
- Enabled point-of-care dose recommendations.
Main Results:
- Algorithm-guided warfarin dosing demonstrates higher accuracy compared to empirical dosing.
- The developed strategy facilitates multiethnic application of pharmacogenetic warfarin dosing.
Conclusions:
- The proposed strategy enhances the accuracy and accessibility of pharmacogenetic-guided warfarin dosing for diverse populations.
- Leveraging electronic health records and genetic testing is crucial for advancing personalized medicine in warfarin therapy.
More Related Videos
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
94
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94
01:27Pharmacogenetics of Drug Metabolism: Overview
90
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
90
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:16Drug toxicity: Idiosyncratic Reactions
127
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
127
01:29Venous Thrombosis III: Interprofessional Care
454
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
454
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
102
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
102